D R Newell - JoVE Visualize

Showing results (41-50 of 120) with videos related to

Pageof 12

Sort By:

British Journal of Cancer|February 1, 1993

Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusionB J Foster, D R Newell, L A Gumbrell, et al.

NMR in Biomedicine|April 1, 1988

Factors affecting 1H NMR spectra of blood plasma: cancer, diet and freezingJ D Bell, J C Brown, R E Norman, et al.

Cancer Treatment Reviews|September 1, 1985

Phase I studies with carboplatin at the Royal Marsden HospitalA H Calvert, S J Harland, D R Newell, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1995

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplementS R Wedge, S Laohavinij, G A Taylor, et al.

Cancer Research|December 1, 1990

Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitorsG Jansen, J H Schornagel, G R Westerhof, et al.

Investigational New Drugs|January 1, 1996

Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study GroupE J Estlin, S Ablett, D R Newell, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000

Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell linesX Lu, J Errington, V J Chen, et al.

Cancer Research|April 1, 1984

Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal functionS J Harland, D R Newell, Z H Siddik, et al.

British Journal of Cancer|September 5, 2001

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogueN R Monks, D C Blakey, N J Curtin, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1986

Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activationC J Rutty, I R Judson, G Abel, et al.

Pageof 12

Showing results (41-50 of 120) with videos related to

Sort By:

Pageof 12

British Journal of Cancer|February 1, 1993

Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusionB J Foster, D R Newell, L A Gumbrell, et al.

NMR in Biomedicine|April 1, 1988

Factors affecting 1H NMR spectra of blood plasma: cancer, diet and freezingJ D Bell, J C Brown, R E Norman, et al.

Cancer Treatment Reviews|September 1, 1985

Phase I studies with carboplatin at the Royal Marsden HospitalA H Calvert, S J Harland, D R Newell, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1995

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplementS R Wedge, S Laohavinij, G A Taylor, et al.

Cancer Research|December 1, 1990

Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitorsG Jansen, J H Schornagel, G R Westerhof, et al.

Investigational New Drugs|January 1, 1996

Phase I trials in paediatric oncology--the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study GroupE J Estlin, S Ablett, D R Newell, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2000

Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell linesX Lu, J Errington, V J Chen, et al.

Cancer Research|April 1, 1984

Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal functionS J Harland, D R Newell, Z H Siddik, et al.

British Journal of Cancer|September 5, 2001

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogueN R Monks, D C Blakey, N J Curtin, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1986

Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activationC J Rutty, I R Judson, G Abel, et al.

Pageof 12